TITLE

Mammalian target of rapamycin: Biological function and target for novel anticancer agents

AUTHOR(S)
Borders, Emily B.; Bivona, Cory; Medina, Patrick J.
PUB. DATE
December 2010
SOURCE
American Journal of Health-System Pharmacy;12/15/2010, Vol. 67 Issue 24, p2095
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Purpose. The biological function of the mammalian target of rapamycin (mTOR) and mechanisms of action of mTOR inhibitors currently available for clinical use are described. Summary. mTOR is a target for anticancer agents due to its role in cancer development, progression, and resistance to other antineoplastic agents. Currently, two mTOR inhibitors, temsirolimus and everolimus, are approved for the treatment of patients with advanced renal cell carcinoma (RCC). Clinical trials comparing single-agent temsirolimus with interferon alfa-2a demonstrated an improvement in overall survival and progression-free survival (PFS) in patients with metastatic RCC. Clinical studies comparing everolimus with placebo indicated improved PFS in advanced RCC patients whose disease had progressed on or after vascular endothelial growth factor (VEGF) inhibitor therapy. Due to its role in the phosphatidylinositol 3-kinase (PI3K) signaling pathway, mTOR is a rational target for inhibition in combination with other agents, including traditional chemotherapy and agents that are affected by or target the PI3K pathway. Data from these studies review the use of mTOR inhibitors in non-Hodgkin's lymphoma and endometrial, breast, and neuroendocrine tumors. Common toxicities of mTOR inhibitors include mucositis, stomatitis, rash, asthenia, fatigue, and myelosuppression. Additional toxicities requiring monitoring include hyperglycemia, hyperlipidemia, and pneumonitis. Conclusion. The mTOR signaling pathway is upregulated in a variety of solid and hematologic tumors. Two inhibitors of this pathway, temsirolimus and everolimus, have been approved for use in metastatic RCC. Although relatively safe, these drugs are associated with some unique adverse effects, such as hyperlipidemia, hyperglycemia, and pneumonitis, that require monitoring and may require clinical intervention.
ACCESSION #
56584763

 

Related Articles

  • Effects of mTOR inhibitors and cytoskeletal-directed agents alone and in combination against normal and neoplastic hematopoietic cells in vitro. Trendowski, Matthew; Christen, Timothy; Andonova, Antoaneta; Narampanawe, Berlini; Thibaud, Ashlee; Kusang, Tenzin; Fondy, Thomas // Investigational New Drugs;Dec2015, Vol. 33 Issue 6, p1162 

    No abstract available.

  • Multicenter Phase II Study of Tivozanib (AV-951) and Everolimus (RAD001) for Patients With Refractory, Metastatic Colorectal Cancer. Wolpin, Brian M.; Kimmie Ng; Zhu, Andrew X.; Abrams, Thomas; Enzinger, Peter C.; Mccleary, Nadine J.; Schrag, Deborah; Kwak, Eunice L.; Allen, Jill N.; Bhargava, Pankaj; Chan, Jennifer A.; Goessling, Wolfram; Blaszkowsky, Lawrence S.; Supko, Jeffrey G.; Elliot, Meaghan; Sato, Kaori; Regan, Eileen; Meyerhardt, Jeffrey A.; Fuchs, Charles S. // Oncologist;Apr2013, Vol. 18 Issue 4, p377 

    Background. Treatments that target the vascular endothelial growth factor (VEGF) pathway have efficacy in colorectal cancer. We evaluated tolerability and efficacy of tivozanib (an oral VEGF receptor-1, -2, -3 inhibitor) plus everolimus (an oral mammalian target of rapamycin inhibitor). Methods....

  • Safety and tolerability of AZD8055 in Japanese patients with advanced solid tumors; a dose-finding phase I study. Asahina, Hajime; Nokihara, Hiroshi; Yamamoto, Noboru; Yamada, Yasuhide; Tamura, Yosuke; Honda, Kazunori; Seki, Yoshitaka; Tanabe, Yuko; Shimada, Hitoshi; Shi, Xiaojin; Tamura, Tomohide // Investigational New Drugs;Jun2013, Vol. 31 Issue 3, p677 

    No abstract available.

  • A pilot trial of the mTOR (mammalian target of rapamycin) inhibitor RAD001 in patients with advanced B-CLL. Decker, Thomas; Sandherr, Michael; Goetze, Katharina; Oelsner, Madlen; Ringshausen, Ingo; Peschel, Christian // Annals of Hematology;Mar2009, Vol. 88 Issue 3, p221 

    Although B-cell chronic lymphocytic leukemia (CLL) is treatable, it remains an incurable disease and most patients inevitably suffer relapse. Many therapeutic options exist for those requiring therapy, including monoclonal antibodies and stem cell transplantation, but remissions tend to last...

  • Translational suppression of HIF-1α by miconazole through the mTOR signaling pathway. Park, Jee-Young; Jung, Hui-Jung; Seo, Incheol; Jha, Bijay; Suh, Seong-Il; Suh, Min-Ho; Baek, Won-Ki // Cellular Oncology (2211-3428);Aug2014, Vol. 37 Issue 4, p269 

    Background: Miconazole is an imidazole antifungal agent that has amply been used in the treatment of superficial mycosis. Preliminary data indicate that miconazole may also induce anticancer effects. As yet, however, little is known about the therapeutic efficacy of miconazole on cancer and the...

  • A randomised phase II trial of selumetinib vs selumetinib plus temsirolimus for soft-tissue sarcomas. Eroglu, Z; Tawbi, H A; Hu, J; Guan, M; Frankel, P H; Ruel, N H; Wilczynski, S; Christensen, S; Gandara, D R; Chow, W A // British Journal of Cancer;5/12/2015, Vol. 112 Issue 10, p1644 

    Background:The MEK inhibitor, selumetinib, suppresses soft-tissue sarcoma (STS) cell proliferation in vitro. Mammalian target of rapamycin inhibitors possess modest activity against STS; however, resistance develops via MAPK pathway feedback activation. The combination of selumetinib and...

  • Bortezomib: friend or foe of hemolytic anemia? Dasanu, Constantin A // Journal of Oncology Pharmacy Practice;Sep2011, Vol. 17 Issue 3, p233 

    Over the last decade, bortezomib moved in a stepwise fashion from a benchside promise into a bedside reality and is currently an important tool in the treatment of plasma cell disorders. This review focuses on the relationship between bortezomib and hemolytic anemia. In animal models with...

  • favorite things. putting the squeeze on CANCER. BRECHKA, NICOLE // Better Nutrition;Aug2011, Vol. 73 Issue 8, p48 

    The article presents an interview with physician and medical researcher Isaac Eliaz. When asked about the life saving benefits of modified citrus pectin (MCP), Eliaz says that the pectin can easily enter the bloodstream and work throughout the body to fight cancer and address other health...

  • Relapsed and/or Refractory Mantle Cell Lymphoma: What Role for Temsirolimus? Kirschey, Sebastian; Wagner, Susanne; Hess, Georg // Clinical Medicine Insights: Oncology;2012, Issue 6, p153 

    Mantle Cell Lymphoma (MCL) is associated with a dismal prognosis. Recently, along with the improved understanding of the pathophysiology of this disease, new first line regimens have been established and in addition novel treatment options have entered the clinical arena. In consequence,...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics